Welcome Guest
Home » Reports » Pharma & Biotech » Antibody Drug Conjugates Market (3rd Edition)

Antibody Drug Conjugates Market (3rd Edition)

Published: Dec 10, 2015
Pages: 357
Product Code: RA10052
License Type :  (Learn More)

The ADC market is being driven by the sales of ADCETRIS® and KADCYLA®, the only two commercially available drugs. It is a relatively new concept with respect to technology, although the individual molecules that form ADCs have been used since long. This new class of therapeutics has witnessed a strong acceptance from both big and small pharmaceutical companies as they try to fill gaps in their respective oncology pipelines. There has been a healthy growth in the number of pipeline molecules (both clinical and preclinical), suggesting a heavy focus of stakeholders in the industry. Majority of the drugs are being developed for oncological indications. In fact, several molecules are designed to target a large bandwidth of cancers, focussing on multiple indications; such molecules form 19% of the clinical pipeline.

 

The field has been abuzz with partnering activities; such collaborations provide a synergistic boom to both the partners in terms of enrichment of product portfolio, revenues and stability. Technology licensing is the preferred model for ADC development. Seattle Genetics and ImmunoGen, the two leading technology developers, have been involved in a number of partnerships. In fact, asignificant proportion of ADCs in development are based on the ADC technology of these two companies.

 

The unexploited and promising nature of this market supports the hopes pinned on multiple start-ups by several strategic investors and venture capital firms. Over 80 instances of funding (equity + debt) were traced during our research, with the total investment amounting to an encouraging sum of USD 1.9 billion over the last decade. In addition to the venture capital firms, big pharma companies have also made strategic investment in smaller companies focused on developing ADCs.

 

A rich pipeline, promising safety / efficacy results and strong backing by venture capital firms is likely to result in a significant growth in the market over the next ten years. In the longer term, several start-ups / university spin-offs, which currently have molecules in preclinical / discovery phase, are expected to sustain the growth momentum.

 

  • Synopsis
  • Table of
    Contents
  • List of
    Figures
  • List of
    Tables
  • Listed Companies
  • Sample
    Pages
  • Download Brochure

 

The “Antibody Drug Conjugates Market (3rd edition), 2015-2025” report provides a comprehensive analysis of the current market landscape and future outlook of the growing pipeline of ADCs. The ADC market has been one of the most actively evolving markets over the last few years and encompasses a myriad of therapies that can be potentially exploited for a broad range of cancer indications.

 

One of the key objectives of the study is to review and quantify the opportunities laid by the robust, opportunistic and broad pipelines of the pharmaceutical firms. With two marketed drugs (ADCETRIS® and KADCYLA®), the market is treading its way towards fulfilling a huge untapped promise. Amongst other elements, the report elaborates on the following key areas:

  • The current state of the market with respect to key players, developmental stage of pipeline products (both clinical / pre-clinical) and indications targeted
  • Technology providers, and key cytotoxin, linker and conjugation technologies supporting the development of improved ADCs
  • Recent partnerships that have taken place over the last decade including product co-development, licensing and clinical trial collaborations
  • Various investments and grants received by the companies focused in this area
  • Therapeutic areas forming the current focus of developers, the gradual drift and expansion towards broader application areas
  • Competitive landscape and inherent threats to growth in the short and long term
  • Development and sales potential, based on target consumer segments, likely adoption rate and expected pricing, of molecules in late stages of development

 

The base year for the report is 2015. The report provides market forecast for the period 2015-2025. The research, analysis and insights presented in this report include potential sales of several ADCs; this analysis is backed by a deep understanding of key drivers behind the growth.

 

Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry’s evolution. All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

 

 

Example Highlights

  1. Driven by the sales of ADCETRIS® and KADCYLA® (the only two drugs currently available commercially), the ADC market is estimated to be worth around USD 0.9 billion in 2015.
  2. The market has a strong clinical pipeline of 53 molecules; nearly one-third of the molecules are in Phase II or Phase III of development. The dynamic pipeline also includes a number of molecules in preclinical/ discovery stage; in our research, we came across over 60 such molecules.
  3. Most commonly used cytotoxins for ADCs under clinical development include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin dominates the market and accounts for over 50% of ADCs in clinical development.
  4. Roche, with six molecules in clinical development, has the most developed pipeline of ADCs. Other established players in the market are (in alphabetical order) AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BMS, GSK, Novartis, Pfizer and Sanofi.
  5. Relative new entrants include (in alphabetical order) AbGenomics, Allozyne, Ambrx, Biotest, Celldex Therapeutics, Centrose, CytomX Therapeutics, Esperance Pharmaceuticals, Formation Biologics, Genmab, Heidelberg Pharma, Igenica, Immunomedics, Oxford BioTherapeutics, Kairos Therapeutics, Merrimack Pharmaceuticals, Mersana Therapeutics, NBE Therapeutics, Philochem, PhotoBiotics, Progenics Pharmaceuticals, Sorrento Therapeutics, Stem CentRx, Sutro Biopharma, Synthon, Zymeworks; emergence of these firms is likely to provide the necessary push, both in terms of technology and innovation.
  6. About 70%-80% of ADC manufacturing is currently outsourced. There are limited number of contract manufacturers with capabilities for development of linkers and cytotoxins. In addition, even fewer CMOs provide conjugation services for ADC.
  7. Several technological developments have taken place in the recent past; more stable linkers and potent cytotoxins are likely to ensure that the next generation ADCs have improved safety/efficacy profile.
  8. With around 10 new ADC commercial launches over the coming decade, we believe the overall market will be worth USD 10 billion annually by 2025.Favourable market environment and regulatory regimes could result in an even steeper growth.

 

 

Research Methodology

Most of the data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

 

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

 

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

 

Chapter Outlines

Chapter 2 presents an executive summary of the report. It offers a high level view on where the ADC market is headed in the mid-long term.

 

Chapter 3 provides a general introduction to the ADCs. In this section, we have discussed, in detail, the concept of ADC, its components, mechanism of action and advantages over traditional therapies.

 

Chapter 4 provides a comprehensive landscape of the ADC market. This chapter has information on all the ADC molecules in development (clinical and preclinical) along with their current phase of development, key targeted indications, companies that are active in the field of ADC and most common types of cytotoxins and linkers used for ADC development.

 

Chapter 5 provides our analysis of the key opinion leaders (KOLs) focused in the ADC research sector. It provides a comprehensive list of principal investigators, along with their respective research institutes, and highlights KOLs who have relatively more experience.

 

Chapter 6 provides a competitive portfolio of various therapies being developed for the treatment of commonly targeted indications. These indications have been the prime focus of companies developing ADCs. The chapter also highlights the epidemiological facts and currently available treatment options for each indication.

 

Chapter 7 presents our analysis on the ADC market opportunity in the upcoming decade. It includes detailed drug profiles and likely sales forecast for drugs currently in phase II or higher stage of development. The profiles cover information such as drug’s mechanism of action, history of development, clinical trial timeline, clinical trial results, manufacturing, estimated cost of treatment and dosage regimen.

 

Chapter 8 provides a comprehensive list of partnerships, including the details of agreements, which have taken place between various companies over the last few years.

 

Chapter 9 provides information on several funding instances that have driven research and development in the field of ADCs. Our analysis reveals interesting insights on the growing interest of venture capitalists and other stakeholders in this market.

 

Chapter 10 includes profiles of the key companies focused in the ADC market. Each company profile includes information such as financial performance, geographical presence, marketed / pipeline ADC drugs and recent collaborations.

 

Chapter 11 presents a case study on ADC manufacturing. The case study discusses the current manufacturing challenges associated with ADCs and provides information on the leading contract manufacturers that are focused in this domain.

 

Chapter 12 provides our analysis of the strengths, weaknesses, opportunities and threats in the ADC market, capturing the key elements likely to influence future growth.

 

Chapter 13 is a collection of interview transcripts; these discussions have helped us in forming a better understanding of the key market dynamics, competitive landscape and the likely future trends in the market. The companies interviewed include Piramal Healthcare, Pierre Fabre, PolyTherics, Oxford BioTherapeutics, Lonza, Catalent Pharma Solutions and BSP Pharmaceuticals. Two additional companies that were interviewed requested the details to be published as anonymous.

 

Chapter 14 summarises the overall report. In this chapter, we have provided a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

 

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

 

Chapter 16 is an appendix, which lists down all the companies and organisations involved in the ADC market.

 

 
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Cancer Treatment
3.3. Cancer Treatment Methods
3.3.1. Surgery
3.3.2. Radiation Therapy
3.3.3. Chemotherapy
3.3.4. Targeted Therapies
3.4. Monoclonal Antibodies to Treat Cancer
3.5. ADCs: Essential Components
3.5.1. Antibody
3.5.2. Cytotoxin
3.5.3. Linker
3.6. Advantages of ADCs Over Traditional Therapeutics
 
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Clinical Pipeline
4.2.1. Distribution by Phases of Development
4.2.2. Distribution by Indications
4.2.3. Distribution by Linkers
4.2.4. Distribution by Cytotoxins
4.2.5. Distribution by Technology Providers
 
4.3. Preclinical Pipeline
4.3.1. Distribution by Phases of Development
4.3.2. Distribution by Indications
4.3.3. Distribution by Geographies
 
5. KOL ANALYSIS
5.1. Background
5.2. Current Research Landscape
5.2.1. ADCETRIS®: Key Opinion Leaders
5.2.2. KADCYLA®: Key Opinion Leaders
5.2.3. Other ADCs: Key Opinion Leaders
5.3. Most Prominent Key Opinion Leaders
 
6. KEY THERAPEUTIC AREAS FOR ADCS
6.1. Chapter Overview
6.2. Haematological Malignancies
6.2.1. Leukaemia and Lymphoma
6.2.1.1. Introduction and Epidemiology: Leukaemia
6.2.1.1.1. Acute Myeloid Leukaemia (AML)
6.2.1.1.2. Chronic Myeloid Leukaemia (CML)
6.2.1.1.3. Acute Lymphocytic Leukaemia (ALL)
6.2.1.1.4. Chronic Lymphocytic Leukaemia (CLL)
 
6.2.1.2. Introduction and Epidemiology: Lymphoma
6.2.1.3. Current Treatment Landscape
6.2.1.3.1. Targeted Therapies
6.2.1.4. ADCs for Leukaemia/Lymphoma
 
6.2.2. Multiple Myeloma
6.2.2.1. Introduction and Epidemiology
6.2.2.2. Current Treatment Landscape
6.2.2.3. ADCs for Multiple Myeloma
 
6.3. Solid Tumours
6.3.1. Metastatic Melanoma
6.3.1.1. Introduction and Epidemiology
6.3.1.2. Current Treatment Landscape
6.3.1.3. ADCs for Metastatic Melanoma
 
6.3.2. Bladder Cancer
6.3.2.1. Introduction and Epidemiology
6.3.2.2. Current Treatment Landscape
6.3.2.3. ADCs For Bladder Cancer
 
6.3.3. Kidney Cancer
6.3.3.1. Introduction and Epidemiology
6.3.3.2. Current Treatment Landscape
6.3.3.3. ADCs for Kidney Cancer
 
6.3.4. Ovarian Cancer
6.3.4.1. Introduction and Epidemiology
6.3.4.2. Current Treatment Landscape
6.3.4.3. ADCs for Ovarian Cancer
 
6.3.5. Breast Cancer
6.3.5.1. Introduction and Epidemiology
6.3.5.2. Current Treatment Landscape
6.3.5.3. ADCs for Breast Cancer
 
6.3.6. Glioblastoma
6.3.6.1. Introduction and Epidemiology
6.3.6.2. Current Treatment Landscape
6.3.6.3. ADCs for Glioblastoma
 
6.3.7. Lung Cancer
6.3.7.1. Introduction and Epidemiology
6.3.7.2. Current Treatment Landscape
6.3.7.3. ADCs for Lung Cancer
 
6.3.8. Colorectal Cancer
6.3.8.1. Introduction and Epidemiology
6.3.8.2. Current Market Landscape
6.3.8.3. ADCs for Colorectal Cancer
 
6.3.9. Prostate Cancer
6.3.9.1. Introduction and Epidemiology
6.3.9.2. Current Market Landscape
6.3.9.3. ADCs for Prostate Cancer
 
7.  UPCOMING ADC DRUGS: DETAILED PROFILES AND MARKET FORECAST
7.1. Chapter Overview
7.2. Overall ADC Market Forecast, 2015 - 2025
7.2.1. Scope and Limitations
7.2.2. Forecast Methodology
7.2.3. ADC Drug Sales Market, 2015 - 2025
7.2.3.1. Overall Sales Forecast, 2015 - 2025: By Type of ADC
7.2.3.1. Overall Sales Forecast, 2015 - 2025: By Type of Linker
7.2.3.2. Overall Sales Forecast, 2015 - 2025: By Type of Cytotoxin
 
7.3. ADCETRIS®/ Brentuximab vedotin (Seattle Genetics / Millennium Pharmaceuticals)
7.3.1. Drug Overview
7.3.2. Mechanism of Action
7.3.3. Cost, Dosage and Reimbursement of ADCETRIS®
7.3.4. Factors Supporting the High Price
7.3.5. Clinical Development
7.3.6. Key Clinical Trial Results
7.3.7. ADCETRIS® Sales, 2011- H1 2015
7.3.8. Strategies for Market Expansion
7.3.9. ADCETRIS® Sales Forecast: Short-Midterm
7.3.10. ADCETRIS® Sales Forecast: Long Term
 
7.4. KADCYLA® / T-DM1 / RG3502 (Genentech / Roche)
7.4.1. Drug Overview
7.4.2. Mechanism of Action
7.4.3. Cost, Dosage and Reimbursement of KADCYLA®
7.4.4. Approval History
7.4.5. Clinical Development
7.4.6. KADCYLA® Sales, 2013 – H1, 2015
7.4.7. KADCYLA® Sales Forecast: Short-Midterm
7.4.8. KADCYLA® Sales Forecast: Long Term
 
7.5. CDX-011/ Glembatumumab Vedotin (Celldex Therapeutics)
7.5.1. Drug Overview
7.5.2. Mechanism of Action
7.5.3. Clinical Development
7.5.4. Key Clinical Trial Results
7.5.5. Competition for CDX-011
7.5.6. CDX-011 Sales Forecast: Long Term
 
7.6. RG7599/ Lifastuzumab Vedotin (Roche / Genentech)
7.6.1. Drug Overview
7.6.2. Mechanism of Action
7.6.3. Clinical Development
7.6.4. Key Clinical Trial Results
7.6.5. Competition For RG7599
7.6.6. RG7599 Sales Forecast: Long Term
 
7.7. BT-062 /Indatuximab Ravtansine (Biotest)
7.7.1. Drug Overview
7.7.2. Mechanism of Action
7.7.3. Clinical Development
7.7.4. Key Clinical Trial Results
7.7.5. Competition for BT-062
7.7.6. BT-062 Sales Forecast:  Long Term
 
7.8. PSMA-ADC (Progenics Pharmaceuticals)
7.8.1. Drug Overview
7.8.2. Mechanism of Action
7.8.3. Clinical Development
7.8.4. Key Clinical Trial Results
7.8.5. Competition for PSMA ADC
7.8.6. PSMA ADC Sales Forecast: Long Term
 
7.9. MM-302 (Merrimack Pharmaceuticals)
7.9.1. Drug Overview
7.9.2. Mechanism of Action
7.9.3. Clinical Development
7.9.4. Key Clinical Trial Results
7.9.5. Competition for MM-302
7.9.6. MM-302 Sales Forecast: Long Term
 
7.10. IMMU-130 (Immunomedics)
7.10.1. Drug Overview
7.10.2. Mechanism of Action
7.10.3. Clinical Development
7.10.4. Key Clinical Trial Results
7.10.5. Competition for IMMU-130
7.10.6. IMMU-130 Sales Forecast: Long Term
 
7.11. CMC-544/ Inotuzumab Ozogamicin (Pfizer)
7.11.1. Drug Overview
7.11.2. Mechanism of Action
7.11.3. Clinical Development
7.11.4. Key Clinical Trial results
7.11.5. Competition for CMC-544
7.11.6. CMC-544 /Inotuzumab Ozogamicin Sales Forecast: Long Term, 2019-2025
 
7.12. RG7596/ Polatuzumab Vedotin (Roche)
7.12.1. Drug Overview
7.12.2. Mechanism of Action
7.12.3. Clinical Development
7.12.4. Key Clinical Trial Results
7.12.5. RG7596 Sales Forecast: Long Term
 
7.13. SAR3419/ Coltuximab Ravtansine (ImmunoGen)
7.13.1. Drug Overview
7.13.2. Mechanism of Action
7.13.3. Clinical Development
7.13.4. Key Clinical Trial Results
7.13.5. Competition for SAR3419
7.13.6. SAR3419 Sales Forecast: Long Term
 
7.14. ABT-414 (AbbVie)
7.14.1. Drug Overview
7.14.2. Mechanism of Action
7.14.3. Clinical Development
7.14.4. Key Clinical Trial Results
7.14.5. Competition for ABT-414
7.14.6. ABT-414 Sales Forecast: Long Term
 
7.15. Other Molecules
 
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.1.1. Type of Partnerships
8.1.2. Number of Partnerships have Increased Overtime
8.1.3. Seattle Genetics and ImmunoGen have been the Most Active Companies
 
9. VENTURE CAPITAL INTEREST
9.1. Chapter Overview
9.2. Instances of Funding in ADCs
9.3. Rising Venture Capital Interest
9.4. Funding Instances: Distribution by Type of Funding
9.5. Leading Players: Distribution by Number of Funding Instances
9.6. Most Active VC Firms/Institutions
 
10. COMPANY PROFILES
10.1. Chapter Overview
10.2. ImmunoGen
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. ADC Pipeline
10.2.4. Collaborations
 
10.3. Seattle Genetics
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. ADC Pipeline
10.3.4. Collaborations
 
10.4. Immunomedics
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. ADC Pipeline
10.4.4. Collaborations
 
10.5. Pfizer
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. ADC Pipeline
10.5.4. Collaborations
 
10.6. Roche / Genentech
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. ADC Pipeline
10.6.4. Collaborations
 
10.7. Celldex Therapeutics
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. ADC Pipeline
10.7.4. Collaborations
 
10.8. Millennium Pharmaceuticals
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. ADC Pipeline
10.8.4. Collaborations
 
10.9. AbbVie
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. ADC Pipeline
10.9.4. Recent Developments
10.9.5. Collaborations
 
10.11. Bayer HealthCare
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. ADC Pipeline
10.11.4. Collaborations
 
10.12. Astellas Pharma/Agensys
10.12.1. Company Overview
10.12.2. Financial Performance
10.12.3. ADC Pipeline
10.12.4. Collaborations
 
10.13. Progenics Pharmaceuticals
10.13.1. Company Overview
10.13.2. Financial Performance
10.13.3. ADC Pipeline
10.13.4. Collaborations
 
10.14. Mersana Therapeutics
10.14.1. Company Overview
10.14.2. ADC Pipeline
10.14.3. Collaborations
 
10.15. Synthon
10.15.1. Company Overview
10.15.2. ADC Pipeline
10.15.3. Collaborations
 
10.16. Heidelberg Pharma
10.16.1. Company Overview
10.16.2. ADC Pipeline
10.16.3. Collaborations
 
10.17. Oxford BioTherapeutics
10.17.1. Company Overview
10.17.2. ADC Pipeline
10.17.3. Collaborations
 
11. CASE IN POINT: CONTRACT MANUFACTURING IN ADCs
11.1. Background
11.2. ADC Drugs: Limited Technology Providers
11.3. ADC Manufacturing: Key Steps
11.4. ADC Manufacturing: Key Challenges
11.5. In-House Manufacturing of ADCs
11.6. Global Presence of Contract Manufacturers
11.7. A Promising Scope For Investment
11.8. Emergence of Start-Ups
11.9. Contract Manufacturers Collaborating to Provide ADC Capabilities
11.10. CMOs Manufacturing Linkers
11.11. CMOs with HPAPI / Cytotoxic Capabilities
11.12. Growing Conjugation Capability
11.13. Full Service Providers for ADCs: An Unmet Need
 
12. SWOT ANALYSIS
12.1. Strengths
12.2. Weaknesses
12.3. Opportunities
12.4. Threats
 
13. INTERVIEW TRANSCRIPTS
13.1. Chapter Overview
13.2. Interview 1: Mark Wright, Site Head, Grangemouth, Piramal Healthcare
13.3. Interview 2: Christian Bailly, Head of CDMO, Pierre Fabre
13.4. Interview 3: Dr. John Burt, CEO, PolyTherics (an Abzena company)
13.5. Interview 4: Christian Rohlff, Founder & CEO, Oxford BioTherapeutics
13.6. Interview 5: Laurent Ducry, ADC R&D, Lonza
13.7. Interview 6: Stacy McDonald, Group Product Manager & Jennifer L. Mitcham, Director - Business Development, Catalent Pharma Solutions
13.8. Interview 7: Aldo Braca, CEO, BSP Pharmaceuticals
13.9.  Interview 8: Director, Business Development, Anonymous CMO
13.10. Interview 9: Chief Executive Officer, Anonymous CMO
 
14. CONCLUSION
14.1. ADCETRIS® and KADCYLA®: The Current Flagbearers
14.2. Several Molecules Likely to Achieve Blockbuster Status
14.3. CMOs Expected to Play a Critical Role in Future Success
14.4. An Attractive Market for Large Pharmaceutical Companies; Start-ups Continue to Emerge
14.5. Collaborations Have Been Widespread; The Trend is Unlikely to Change
14.6. Concluding Remarks
 
15. APPENDIX 1: TABULATED DATA
 
16. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS
 
 
 
Figure 3.1 Timeline of Cancer Treatments
 
Figure 3.2 Cancer Treatments: Type of Surgeries
 
Figure 3.3 Cancer Treatments: Type of Radiation Therapies
 
Figure 3.4 Cancer Treatments: Type of Chemotherapies
 
Figure 3.5 Components of ADC
 
Figure 4.1 ADC Clinical Pipeline: Distribution by Phases of Development
 
Figure 4.2 ADC Clinical Pipeline: Distribution by Indications
 
Figure 4.3 ADC Clinical Pipeline: Distribution by Linkers
 
Figure 4.4 ADC Clinical Pipeline: Distribution by Cytotoxins
 
Figure 4.5 ADC Clinical Pipeline: Distribution by Technology Providers
 
Figure 4.6 ADC Preclinical / Discovery Pipeline: Distribution by Phases of Development
 
Figure 4.7 ADC Preclinical Pipeline: Distribution by Indications
 
Figure 4.9 ADC Preclinical Pipeline: Distribution by Geographies
 
Figure 5.1 ADCETRIS®: Mapping Prominent Researchers
 
Figure 5.2 KADCYLA®: Mapping Prominent Researchers
 
Figure 5.3 Other ADCs: Mapping Prominent Researchers
 
Figure 5.4 ADC: Prominent Key Opinion Leaders
 
Figure 6.1 Most Common Types of Leukaemia
 
Figure 6.2 Leukaemia: Global Epidemiological Distribution
 
Figure 6.3 Lymphoma: Global Epidemiological Distribution
 
Figure 6.4 Multiple Myeloma: Global Epidemiological Distribution
 
Figure 6.5 Melanoma: Global Epidemiological Distribution
 
Figure 6.6 Bladder Cancer: Global Epidemiological Distribution
 
Figure 6.7 Kidney Cancer: Global Epidemiological Distribution
 
Figure 6.8 Ovarian Cancer: Global Epidemiological Distribution
 
Figure 6.9 Breast Cancer: Global Epidemiological Distribution
 
Figure 6.10 Lung Cancer: Types
 
Figure 6.11 Lung Cancer: Global Epidemiological Distribution
 
Figure 6.12 Colorectal Cancer: Global Epidemiological Distribution
 
Figure 6.13 Prostate Cancer: Global Epidemiological Distribution
 
Figure 7.1 ADC Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
 
Figure 7.2 ADC Sales Forecast, 2015 - 2025: By Type of ADC (USD Million)
 
Figure 7.3 ADC Sales Forecast, 2015 - 2025: By Type of Linker (USD Million)
 
Figure 7.4 ADC Sales Forecast, 2015 - 2025: By Type of Cytotoxin (USD Million)
 
Figure 7.5 ADCETRIS®: Registered Clinical Trials
 
Figure 7.6 ADCETRIS® Sales: 2011 – H1, 2015 (USD Million)
 
Figure 7.7 ADCETRIS® Market (USD Million), Short-Midterm Forecast: (Base Scenario)
 
Figure 7.8 ADCETRIS® Market (USD Million), Long Term Forecast: (Base Scenario)
 
Figure 7.9 KADCYLA®: Registered Clinical Trials
 
Figure 7.10 KADCYLA® Sales, 2013 – H1, 2015 (CHF Million)
 
Figure 7.11 KADCYLA® / T-DM1 Market (USD Million), Short-Midterm Forecast: (Base Scenario)
 
Figure 7.12 KADCYLA® / T-DM1 Market (USD Million), Long Term Forecast: (Base Scenario)
 
Figure 7.13 CDX-011: Registered Clinical Trials
 
Figure 7.14 CDX-011/ Glembatumumab Vedotin Market (USD Million), Long Term Forecast: (Base Scenario)
 
Figure 7.15 RG7599: Registered Clinical Trials
 
Figure 7.16 RG7599 Market (USD Million), Long Term Forecast: (Base Scenario)
 
Figure 7.17 BT-062 Market (USD Million), Long Term Forecast: (Base Scenario)
 
Figure 7.18 PSMA-ADC: Registered Clinical Trials
 
Figure 7.19 PSMA ADC Market (USD Million), Long Term Forecast: (Base Scenario)
 
Figure 7.20 MM-302 Market (USD Million), Long Term Forecast: (Base Scenario)
 
Figure 7.21 IMMU-130: Registered Clinical trials
 
Figure 7.22 IMMU-130 Market (USD Million), Long Term Forecast: (Base Scenario)
 
Figure 7.23 CMC-544: Registered Clinical Trials
 
Figure 7.24 CMC-544/ Inotuzumab Ozogamicin Market (USD Million), Long Term Forecast: (Base Scenario)
 
Figure 7.25 RG7596: Registered Clinical Trials
 
Figure 7.26 RG7596 Market (USD Million), Long Term Forecast: (Base Scenario)
 
Figure 7.27 SAR3419: Registered Clinical Trials
 
Figure 7.28 SAR3419 Market (USD Million), Long Term Forecast: (Base Scenario)
 
Figure 7.29 ABT-414 Market (USD Million), Long Term Forecast: (Base Scenario)
 
Figure 7.30 BAY94-9343 Market (USD Million), Long Term Forecast: (Base Scenario)
 
Figure 7.31 IMMU-132 Market (USD Million), Long Term Forecast: (Base Scenario)
 
Figure 8.1 ADC: Partnerships, 2005 - 2015
 
Figure 8.2 ADC Partnerships: Major Stakeholders
 
Figure 9.1 Cumulative Funding Instances, Pre 2005 - 2015
 
Figure 9.2 Funding Instances: Total Amount Invested Annually (USD Million)
 
Figure 9.3 Funding Instances: Distribution by Type, Pre 2005 - 2015
 
Figure 9.4 Funding Instances: Distribution by Total Amount Invested, (USD Million)
 
Figure 9.5 Most Active Players: Distribution by Number of Funding Instances
 
Figure 9.6 Most Active VC Firms: Evaluation by Number of Instances
 
Figure 10.1 ImmunoGen: Revenues (USD Million), 2011 – 2015
 
Figure 10.2 Seattle Genetics: Revenues (USD Million), 2010 - H1 2015
 
Figure 10.3 Immunomedics: Revenues (USD Million), 2011 – 2015 
 
Figure 10.4 Pfizer: Revenues (USD Billion), 2010 – H1, 2015
 
Figure 10.5 Roche: Revenues (CHF Billion), 2011 – H1, 2015
 
Figure 10.6 Roche: Segment Sales (CHF Billion), 2010 – H1, 2015
 
Figure 10.7 Celldex Therapeutics: Revenues (USD Million), 2010 - H1, 2015
 
Figure 10.8 Takeda Pharmaceuticals: Revenues (JPY Billion), 2010 - 2014
 
Figure 10.9 AbbVie: Revenues (USD Billion), 2010 - Q3, 2015
 
Figure 10.10 Bayer HealthCare: Revenues (EUR Billion), 2010 - Q3, 2015
 
Figure 10.11 Astellas Pharma: Revenues (JPY Billion), 2011 - 2015
 
Figure 10.12 Progenics Pharmaceuticals: Revenues (USD Million), 2010 – 2014
 
Figure 11.1 ADC Market Forecast (USD Million): 2015, 2020 and 2025
 
 
Table 3.1 FDA Approved Antibody Based Therapeutics for Cancer
 
Table 3.2 Commonly Used Cytotoxins for ADC Therapeutics
 
Table 3.3 OEL Bands, Safebridge Consultants
 
Table 4.1 ADCs: Marketed and Development Pipeline
 
Table 4.2 ADCs: Preclinical Pipeline
 
Table 5.1 ADCs: Principal Investigators
 
Table 6.1 Comparison of HL and NHL
 
Table 6.2 Comparison of Marketed Targeted Therapeutics: Leukaemia
 
Table 6.3 Comparison of Marketed Targeted Therapeutics: Lymphoma
 
Table 6.4 ADCs for Leukaemia and Lymphoma
 
Table 6.5 Comparison of Marketed Targeted Therapeutics: Multiple Myeloma
 
Table 6.6 ADCs for Multiple Myeloma
 
Table 6.7 Comparison of Marketed Targeted Therapeutics: Melanoma
 
Table 6.8 ADCs for Metastatic Melanoma
 
Table 6.9 ADCs for Bladder Cancer
 
Table 6.10 Comparison of Marketed Targeted Therapeutics: RCC
 
Table 6.11 ADCs for Kidney Cancer
 
Table 6.12 ADCs for Ovarian Cancer
 
Table 6.13 Comparison of Marketed Therapeutics: Breast Cancer
 
Table 6.14 ADCs for Breast Cancer
 
Table 6.15 ADCs for Glioblastoma
 
Table 6.16 Comparison of Marketed Therapeutics: Lung Cancer
 
Table 6.17 ADCs for Lung Cancer
 
Table 6.18 Comparison of Marketed Therapeutics: Colorectal Cancer
 
Table 6.19 ADCs for Colorectal Cancer
 
Table 6.20 Comparison of Marketed Therapeutics: Prostate Cancer
 
Table 6.21 ADCs for Prostate Cancer
 
Table 7.1 ADCs: Marketed/ Late Stage Molecules
 
Table 7.2 ADCETRIS®/ Brentuximab vedotin: Ongoing Clinical Trials
 
Table 7.3 KADCYLA® / T-DM1: Ongoing Clinical Trials
 
Table 7.4 CDX-011/ Glembatumumab Vedotin: Ongoing Clinical Trials
 
Table 7.5 RG7599/ Lifastuzumab Vedotin: Ongoing Clinical Trials
 
Table 7.6 BT-062: Ongoing Clinical Trials
 
Table 7.7 Comparison of Drugs Available for Metastatic Castration Resistant Prostate Cancer
 
Table 7.8 MM-302: Ongoing Clinical Trials
 
Table 7.9 IMMU-130: Ongoing Clinical Trials
 
Table 7.10 CMC-544/ Inotuzumab Ozogamicin: Ongoing Clinical Trials
 
Table 7.11 RG7596/ Polatuzumab Vedotin: Ongoing Clinical Trials
 
Table 7.12 SAR3419/ Coltuximab Ravtansine: Ongoing Clinical Trials
 
Table 7.13 ABT-414: Ongoing Clinical Trials
 
Table 8.1 List of Partnerships in the Field of ADCs, 2000 - 2015
 
Table 9.1 List of Funding Instances in ADCs
 
Table 9.2 Types of Funding Instances, 1998-2015
 
Table 10.1 ImmunoGen ADC Pipeline, 2015
 
Table 10.2 Seattle Genetics ADC Pipeline, 2015
 
Table 10.3 Immunomedics ADC Pipeline, 2015
 
Table 10.4 Pfizer / Wyeth ADC Pipeline, 2015
 
Table 10.5 Roche / Genentech ADC Pipeline, 2015
 
Table 10.6 Celldex Therapeutics ADC Pipeline, 2015
 
Table 10.7 Millennium Pharmaceuticals ADC Pipeline, 2015
 
Table 10.8 AbbVie ADC Pipeline, 2015
 
Table 10.9 Bayer HealthCare ADC Pipeline, 2015
 
Table 10.12 Mersana Therapeutics ADC Pipeline, 2015
 
Table 11.1 List of Contract Manufacturers and Their Capabilities in ADC Manufacturing
 
Table 11.2 CMOs Offering ADC Conjugation Services
 
Table 11.3 Full Service Contract Manufacturers for ADCs
 
Table 9.1 SWOT Analysis
 
Table 15.1 ADC Clinical Pipeline: Distribution by Phases of Development
 
Table 15.2 ADC Clinical Pipeline: Distribution by Indications
 
Table 15.3 ADC Clinical Pipeline: Distribution by Linkers
 
Table 15.4 ADC Clinical Pipeline: Distribution by Cytotoxins
 
Table 15.5 ADC Clinical Pipeline: Distribution by Technology Developers
 
Table 15.6 ADC Preclinical / Discovery Pipeline: Distribution by Phases of Development
 
Table 15.7 ADC Preclinical / Discovery Pipeline: Distribution by Indications
 
Table 15.8 ADC Preclinical / Discovery Pipeline: Distribution by Geographies
 
Table 15.9 ADC Sales Forecast, 2015- 2025: Conservative Scenario (USD Million)
 
Table 15.10 ADC Sales Market Forecast, 2015- 2025: Base Scenario (USD Million)
 
Table 15.11 ADC Sales Market Forecast, 2015-2025: Optimistic Scenario (USD Million)
 
Table 15.12 ADC Sales Forecast by Type of ADCs, 2015-2025: Conservative Scenario (USD Million)
 
Table 15.13 ADC Sales Forecast by Type of ADCs 2015-2025: Base Scenario (USD Million)
 
Table 15.14 ADC Sales Forecast by Type of ADCs 2015-2025: Optimistic Scenario (USD Million)
 
Table 15.15 ADC Sales Forecast by Type of Cytotoxin (2015-2025): Conservative Scenario (USD Million)
 
Table 15.16 ADC Sales Forecast by Type of Cytotoxin (2015-2025): Base Scenario (USD Million)
 
Table 15.17 ADC Sales Forecast by Type of Cytotoxin (2015-2025): Optimistic Scenario (USD Million)
 
Table 15.18 ADC Sales Forecast by Type of Linker (2015-2025): Conservative Scenario (USD Million)
 
Table 15.19 ADC Sales Forecast by Type of Linker (2015-2025): Base Scenario (USD Million)
 
Table 15.20 ADC Sales Forecast by Type of Linker (2015-2025): Optimistic Scenario (USD Million)
 
Table 15.21 ADCETRIS®: Registered Clinical Trials
 
Table 15.22 ADCETRIS® Market (USD Million), Short-Midterm Forecast: Conservative Scenario
 
Table 15.23 ADCETRIS® Market (USD Million), Short-Midterm Forecast:Base Scenario
 
Table 15.24 ADCETRIS® Market (USD Million), Short-Midterm Forecast:Optimistic Scenario
 
Table 15.25 ADCETRIS® Market (USD Million), Long Term Forecast:Conservative Scenario
 
Table 15.26 ADCETRIS® Market (USD Million), Long Term Forecast:Base Scenario
 
Table 15.27 ADCETRIS® Market (USD Million), Long Term Forecast:Optimistic Scenario
 
Table 15.28 KADCYLA®: Registered Clinical Trials
 
Table 15.29 KADCYLA® / T-DM1 Market (USD Million), Short-Midterm Forecast: Conservative Scenario
 
Table 15.30 KADCYLA® / T-DM1 Market (USD Million), Short-Midterm Forecast: Base Scenario
 
Table 15.31 KADCYLA® / T-DM1 Market (USD Million), Short-Midterm Forecast: Optimistic Scenario
 
Table 15.32 KADCYLA® / T-DM1 Market (USD Million), Long Term Forecast: Conservative Scenario
 
Table 15.33 KADCYLA® / T-DM1 Market (USD Million), Long Term Forecast: Base Scenario
 
Table 15.34 KADCYLA® / T-DM1 Market (USD Million), Long Term Forecast: Optimistic Scenario
 
Table 15.35 CDX-011: Registered Clinical Trials
 
Table 15.36 CDX-011 Market (USD Million), Long Term Forecast: Conservative Scenario
 
Table 15.37 CDX-011 Market (USD Million), Long Term Forecast: Base Scenario
 
Table 15.38 CDX-011 Market (USD Million), Long Term Forecast: Optimistic Scenario
 
Table 15.39 RG7599: Registered Clinical Trials
 
Table 15.40 RG7599 Market (USD Million), Long Term Forecast: Conservative Scenario
 
Table 15.41 RG7599 Market (USD Million), Long Term Forecast: Base Scenario
 
Table 15.42 RG7599 Market (USD Million), Long Term Forecast: Optimistic Scenario
 
Table 15.43 BT-062 Market (USD Million), Long Term Forecast: Conservative Scenario
 
Table 15.44 BT-062 Market (USD Million), Long Term Forecast: Base Scenario
 
Table 15.45 BT-062 Market (USD Million), Long Term Forecast: Optimistic Scenario
 
Table 15.46 PSMA ADC: Registered Clinical Trials
 
Table 15.47 PSMA ADC Market (USD Million), Long Term Forecast: Conservative Scenario
 
Table 15.48 PSMA ADC Market (USD Million), Long Term Forecast: Base Scenario
 
Table 15.49 PSMA ADC Market (USD Million), Long Term Forecast: Optimistic Scenario
 
Table 15.50 MM-302 Market (USD Million), Long Term Forecast: Conservative Scenario
 
Table 15.51 MM-302 Market (USD Million), Long Term Forecast: Base Scenario
 
Table 15.52 MM-302 Market (USD Million), Long Term Forecast: Optimistic Scenario
 
Table 15.53 IMMU-130: Registered Clinical Trials
 
Table 15.54 IMMU-130 Market (USD Million), Long Term Forecast: Conservative Scenario
 
Table 15.55 IMMU-130 Market (USD Million), Long Term Forecast: Base Scenario
 
Table 15.56 IMMU-130 Market (USD Million), Long Term Forecast: Optimistic Scenario
 
Table 15.57 CMC-544: Registered Clinical Trials
 
Table 15.58 CMC-544 Market (USD Million), Long Term Forecast: Conservative Scenario
 
Table 15.59 CMC-544 Market (USD Million), Long Term Forecast: Base Scenario
 
Table 15.60 CMC-544 Market (USD Million), Long Term Forecast: Optimistic Scenario
 
Table 15.61 RG7596: Registered Clinical Trials
 
Table 15.62 RG7596 Market (USD Million), Long Term Forecast: Conservative Scenario
 
Table 15.63 RG7596 Market (USD Million), Long Term Forecast: Base Scenario
 
Table 15.64 RG7596 Market (USD Million), Long Term Forecast: Optimistic Scenario
 
Table 15.65 SAR 3419: Registered Clinical Trials
 
Table 15.66 SAR 3419 Market (USD Million), Long Term Forecast: Conservative Scenario
 
Table 15.67 SAR 3419 Market (USD Million), Long Term Forecast: Base Scenario
 
Table 15.57 SAR 3419 Market (USD Million), Long Term Forecast: Optimistic Scenario
 
Table 15.69 ABT-414 Market (USD Million), Long Term Forecast: Conservative Scenario
 
Table 15.70 ABT-414 Market (USD Million), Long Term Forecast: Base Scenario
 
Table 15.71 ABT-414 Market (USD Million), Long Term Forecast: Optimistic Scenario
 
Table 15.72 BAY949343 Market (USD Million), Long Term Forecast: Conservative Scenario
 
Table 15.73 BAY949343 Market (USD Million), Long Term Forecast: Base Scenario
 
Table 15.74 BAY949343 Market (USD Million), Long Term Forecast: Optimistic Scenario
 
Table 15.75 IMMU132 Market (USD Million), Long Term Forecast: Conservative Scenario
 
Table 15.76 IMMU132 Market (USD Million), Long Term Forecast: Base Scenario
 
Table 15.77 IMMU132 Market (USD Million), Long Term Forecast: Optimistic Scenario
 
Table 15.78 ADC: Partnerships, 2005-2015
 
Table 15.79 ADC Partnerships: Major Stakeholders
 
Table 15.80 Funding: Cumulative Number of Investments by Year, 1998-2015
 
Table 15.81 Funding Instances: Total Amount Invested Annually (USD Million)
 
Table 15.82 Funding Instances: Distribution by Type, 1998-2015
 
Table 15.83 Funding Instances: Distribution by Total Amount Invested, 1998-2015
 
Table 15.84 Most Active Players: Distribution by Number Funding Instances
 
Table 15.85 Most Active VC Firms: Evaluation by Number Funding Instances
 
Table 15.86 ImmunoGen: Revenues (USD Million), 2011-2015
 
Table 15.87 Seattle Genetics: Revenues (USD Million), 2010-H1, 2015
 
Table 15.88 Immunomedics: Revenues (USD Million), 2011- 2015
 
Table 15.89 Pfizer: Revenues (USD Billion), 2010- H1, 2015
 
Table 15.90 Roche: Revenues (CHF Billion), 2010- H1, 2015
 
Table 15.91 Roche: Segment Revenues (CHF Billion), 2010-H1, 2015
 
Table 15.92 Celldex Therapeutics: Revenues (USD Billion), 2010- H1, 2015
 
Table 15.93 Takeda Pharmaceuticals (JPY Billion): Revenues, 2010- 2014
 
Table 15.94 AbbVie: Revenues (USD Billion), 2010- Q3, 2015
 
Table 15.95 Bayer HealthCare: Revenues (EUR Billion), 2010- Q3, 2015
 
Table 15.96 Astellas Pharma: Revenues (JPY Billion), 2011- 2015
 
Table 15.97 Progenics Pharmaceuticals: Revenues (USD Million), 2010- 2014
 
Table 15.98 ADC Market Forecast (USD Million): 2015, 2020, 2025
 

 

Following companies and organisations have been mentioned in this report.

  1. AAIPharma Services Corp
  2. AB SCIEX
  3. AbbVie
  4. AbGenomics
  5. Abramson Cancer Center of the University of Pennsylvania
  6. Abraxis BioScience
  7. Academic and Community Cancer Research United
  8. Academic Medical Center,  University of Amsterdam
  9. ACES Pharma
  10. ADC Therapeutics
  11. Adimab
  12. Affinity Lifesciences
  13. Agensys
  14. AIDS Malignancy Consortium
  15. Algeta
  16. Allos Therapeutics
  17. Allozyne
  18. ALMAC Group
  19. Ambrx
  20. American Cancer Society
  21. American Society of Clinical Oncology (ASCO)
  22. American Society of Haematology, San Francisco
  23. AmerisourceBergen Corporation
  24. Amgen
  25. AMRI Global
  26. Asan Medical Center
  27. Aspyrian Therapeutics
  28. Astellas Pharma
  29. AstraZeneca
  30. Asymchem
  31. Avid Biologics
  32. Bachem
  33. Barbara Ann Karmanos Cancer Institute
  34. Baxter BioPharma Solutions
  35. Bayer Healthcare
  36. Beatson West of Scotland Cancer Center
  37. BioAgilytix Labs
  38. Biogen Idec
  39. BioOutsource
  40. BioPharma Solutions
  41. Biotechnique
  42. Biotecnol
  43. Biotest
  44. BioWa
  45. Boehringer Ingelheim
  46. Bristol-Myers Squibb
  47. Brown University
  48. BSP Pharmaceuticals
  49. Cambrex Corporation
  50. Cancer Institute of Lorraine
  51. Cancer Research Technology (CRT), UK
  52. Cancer Research, UK
  53. Cancer Treatment Centers of America
  54. Cantonal Hospital of St. Gallen
  55. CARBOGEN AMCIS
  56. Cardinal Health
  57. Catalent Pharma Solution
  58. Celgene
  59. Celldex Therapeutics
  60. Centers for Disease Control and Prevention
  61. Centre Hospitalier Lyon Sud, France
  62. Centre Oscar Lambret
  63. Centrose
  64. ChemCon
  65. ChemPartner
  66. Children's Oncology Group
  67. Chu de Limoges
  68. Chugai Pharmaceutical
  69. City of Hope Medical Center
  70. CMC Biologics
  71. Coldstream Laboratories
  72. Columbia University
  73. Concortis
  74. Creative Biolabs
  75. CuraGen
  76. Cytogen Corporation
  77. CytomX Therapeutics
  78. Cytovance Biologics LLC
  79. Daiichi Sankyo
  80. Dalton Pharma Services
  81. Dana-Farber Cancer Institute
  82. Dendreon Corporation
  83. Dishman Group
  84. ECOG-ACRIN Cancer Research Group
  85. EirGenix
  86. Eisai
  87. Elder Pharmaceuticals
  88. Eli Lilly
  89. Endo Pharmaceuticals
  90. Endocyte
  91. Esperance Pharmaceuticals
  92. Eucodis
  93. European Organisation for Research and Treatment of Cancer
  94. Evonik
  95. Ferring Pharmaceuticals
  96. Ferro Pfanstiehl
  97. Fidelity Biosciences
  98. Formation Biologics
  99. Formosa Laboratories
  100. Fox Chase Cancer Center
  101. FUJIFILM Diosynth Biotechnologies
  102. Genentech
  103. General Hospital Linz
  104. Genmab
  105. Genzyme
  106. German Federal Ministry of Education and Research
  107. Gilead Sciences
  108. GLOBOCAN
  109. Goodwin Biotechnology
  110. GSK
  111. GTC Biotherapeutics
  112. Guys Hospital
  113. H. Lee Moffitt Cancer Center & Research Institute Dept of Onc
  114. Harris and Harris Group
  115. Hartmann Oncology Radiotherapy Group
  116. Heidelberg Pharma
  117. Heraeus
  118. Hospital Ramon y Cajal, Madrid, Spain
  119. Hospital Saint-Louis
  120. Hospital Universitario de Salamanca
  121. iBIOSOURCE
  122. ICM
  123. IDT Australia
  124. Igenica
  125. ImClone Systems
  126. Immunogen
  127. Immunomedics
  128. INC Research
  129. Innsbruck Medical University
  130. Institut Bergonié, Bordeaux
  131. Institut Curie
  132. Invenra
  133. IRCCS AOU San Martino
  134. IUHealth Goshen Center for Cancer Care
  135. Janssen Biotech
  136. Johnson & Johnson
  137. Jules Bordet Institute
  138. Kairos Therapeutics
  139. Karolinska university hospital
  140. Kemwell
  141. Korea Cancer Center Hospital
  142. Leica Biosystems
  143. Leukaemia and Lymphoma Society
  144. Life Science Pharmaceuticals
  145. Ligand Pharmaceuticals
  146. Lonza
  147. Lymphoma Study Association
  148. M D Anderson Cancer Center
  149. MAB Discovery
  150. MacroGenics
  151. Massachusetts General Hospital
  152. Mayo Clinic
  153. McKesson Corporation
  154. Medarex
  155. Medical College of Wisconsin
  156. Medical University of Vienna
  157. MedImmune
  158. Medivation
  159. MedStar Washington Hospital Center
  160. Memorial Sloan-Kettering Cancer Center
  161. Menarini
  162. Merck
  163. Merrimack Pharmaceuticals
  164. Mersana Therapeutics
  165. Millenium Pharmaceuticals
  166. MiMabs
  167. Molecular Insight Pharmaceuticals
  168. Morphotek
  169. Natco Pharma
  170. National Cancer Center of Korea
  171. National Cancer Institute
  172. National Research Council of Canada
  173. NBE Therapeutics
  174. New Enterprise Associates
  175. New York Medical College
  176. Nordic Nanovector
  177. Norfolk and Norwich Hospital
  178. Northwestern University
  179. Nottingham University Hospitals NHS Trust
  180. Novartis
  181. Novasep
  182. Novella Clinical
  183. NSABP Foundation
  184. Ohio State University
  185. Oncology Institute of Southern Switzerland
  186. Oncology-Rinat Research and Development (ORRD)
  187. Ono Pharmaceutical
  188. Onyx Pharmaceuticals
  189. Oslo University Hospital
  190. Oxford BioTherapeutics
  191. Pacific GMP
  192. Patheon
  193. Pfizer
  194. Pharmacyclics
  195. Philochem
  196. Philogen
  197. PhotoBiotics
  198. Pierre Fabre Group
  199. Piramal Pharma Solutions
  200. PolyTherics
  201. Princess Margaret Hospital
  202. Progenics Pharmaceuticals
  203. Project Pharmaceutics
  204. ProQuest Investments
  205. PureTech Ventures
  206. QPS Holdings
  207. Quanta BioDesign
  208. Queen Elizabeth Hospital
  209. Recepta Biopharma
  210. Redwood Bioscience
  211. Regional Center for the Fight Against Cancer
  212. Roche
  213. Royal Liverpool Hospital
  214. S. Orsola Malpighi
  215. SAFC
  216. SafeBridge Consultants
  217. Sandoz
  218. Sanofi
  219. Sarah Cannon Research Institute
  220. SCRI Innovations
  221. Seattle Genetics
  222. Seoul National University Hospital
  223. Seragon Pharmaceuticals
  224. Severance Hospital
  225. Shanghai Fosun Pharma
  226. Sigma-Aldrich Corporation
  227. Societa Italiana Corticosteroidi
  228. Society for Neuro-Oncology (SNO), Miami
  229. Sorrento Therapeutics
  230. Southampton General Hospital
  231. Southwest Oncology Group
  232. Spectrum Pharmaceuticals
  233. Spirogen
  234. St James University Hospital
  235. St. Jude Children's Research Hospital
  236. Stem CentRx
  237. Sutro Biopharma
  238. Symbiosis Pharmaceutical Services
  239. Syntarga
  240. Synthon
  241. Takeda Pharmaceutical
  242. The Chemistry Research Solution
  243. The Christie Hospital
  244. The Churchill Hospital,UK
  245. The Freeman Hospital
  246. The Institute of Haematology in Bologna
  247. The Methodist Hospital System
  248. Tuas Biomedical Park
  249. TUBE Pharma
  250. UCB Pharma
  251. UCL School of Pharmacy
  252. UCLA Jonsson Comprehensive Cancer Center
  253. Union Chimique Belge
  254. University Hospital of Wales
  255. University Hospital, UK
  256. University Hospitals Seidman Cancer Center
  257. University of Alabama
  258. University of Amsterdam
  259. University of California
  260. University of Cologne
  261. University of Kansas Medical Center Research Institute
  262. University of Modena and Reggio Emilia
  263. University of Munich
  264. University of Oklahoma Stephenson Cancer Center
  265. University of Texas Health Science Center
  266. University of Ulm
  267. University of Washington Cancer Consortium
  268. UT Southwestern Medical Center
  269. UZ Leuven Hospital
  270. Valeant Pharmaceutical
  271. Vanderbilt-Ingram Cancer Center
  272. Ventana Medical Systems
  273. Victor Hugo Surgical Clinic
  274. Virginia Cancer Specialists, PC
  275. VivaMab
  276. Washington University School of Medicine
  277. Waters
  278. Watson Pharmaceuticals
  279. Weill Medical College of Cornell University
  280. Western Regional Medical Center
  281. WILEX
  282. WuXi PharmaTech
  283. Wyeth
  284. Zhejiang Medicine Co. (ZMC)
  285. Zymeworks 

 

Following venture capital firms / investors have been mentioned in this report.

  1. 5AM Ventures
  2. Advanced Biotechnologies Venture Fund
  3. Advantage Capital Partners
  4. Advent Venture Partners
  5. Alexandria Real Estate Equities
  6. Alta Partners
  7. Amgen Ventures
  8. Apax Partner
  9. Apposite Capital
  10. Aravis Ventures
  11. ARCH Venture Partners
  12. Auven Therapeutics
  13. BankInvest Group
  14. Bear Sterns Health Innoventures
  15. Boehringer Ingelheim Venture Fund
  16. BSI
  17. Canaan Partners
  18. Carnegie Kapitalforvaltning
  19. Cascade Investment
  20. Casdin Capital
  21. Catapult Ventures
  22. Cooley Godward Kronish
  23. Cormorant Asset Management
  24. Credit Suisse First Boston Next Fund
  25. Crocker Ventures
  26. CTI Life Sciences Fund
  27. Dansk Erhvervsinvestering
  28. Deerfield Management
  29. Dow Venture Capital
  30. Duquesne Capital Management
  31. Expansion Venture Capital
  32. Fidelity Investments
  33. Fred Alger Management
  34. Glynn Capital Management
  35. H&Q Life Sciences Investments
  36. Hambrecht & Quist Capital Management
  37. HBM BioVentures
  38. HBM Partners
  39. HealthCap Venture Capital
  40. Hercules Technology Growth Capital
  41. HNI Holdings
  42. Index Ventures
  43. Innovis Investments
  44. International Biotechnology Trust
  45. Iroquois Capital Group
  46. JAFCO
  47. Jennison Associates
  48. Lilly Ventures
  49. LODH Private Equity Partners
  50. Lombard Odier Darier Hentsch & Cie
  51. Maverick Capital
  52. Modal Capital L.P.
  53. MPM Capital
  54. MS Seed Capital
  55. MS Ventures
  56. Nextech Venture
  57. Noonday Asset Management
  58. Orbimed Advisors
  59. OVP Venture Partners
  60. Oxford Capital Partners
  61. Perceptive Advisors
  62. Pfizer Venture Investments
  63. Presidio Partners
  64. Redmile Group
  65. ReqMed Company
  66. Research Corporation Technologies
  67. Roche Venture Fund
  68. Scale Venture Partners
  69. Scottish Widows Investment Partnership
  70. Silicon Valley Bank
  71. Skyline Ventures
  72. Sofinnova Ventures
  73. Sorenson Development
  74. South East Growth Fund & Management
  75. Suez Ventures
  76. SV Life Sciences
  77. Tavistock Life Sciences
  78. Tekla Healthcare investors & Tekla Life Science Investors
  79. The Column Group
  80. Themelios Ventures
  81. Third Rock Ventures
  82. TPG-Axon Capital
  83. Twilight Venture Partners
  84. Unilever Technology Ventures Fund B.V.
  85. Union Carbide Employees Pension Plan
  86. Venrock Healthcare Capital Partners
  87. Venture Associates
  88. Ventures West Capital
  89. Versant Ventures
  90. VLG Investments
  91. Vulcan Capital
  92. Wellington Management Company
  93. Wharton Biotechnology Partners
  94. WT Investment Advisors Fund
  95. Ziff Asset Management
  96. Zroche Venture Fund

 

You may also like

Copyright © Roots Analysis. All Rights Reserved.
website security